spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Scitara and Veeva Partner to Help Companies Optimize QC Lab Productivity

Scitara




Marlborough, MA, October 18th – Innovator in laboratory digital transformation, Scitara, announces a new partnership with Veeva, the global leader in cloud software for the life sciences industry. The partnership will bring together Scitara’s strength in lab instrument solutions with Veeva’s quality assurance (QA) and quality control (QC) software to help companies improve data integrity, maximize lab productivity, and accelerate batch release.

Scitara is transforming instrument and application integration throughout the laboratory ecosystem with its scientific integration platform SIP, a peer-to-peer iPaaS for science. Scitara’s SIP and flagship technology, digital lab exchange DLX, are complementary to Veeva Vault LIMS, a modern laboratory information management system (LIMS) that streamlines sample tracking, test execution, and lab processes to optimize for real-time batch release.

With QC being a critical step of the manufacturing process before drugs and therapeutics reach the market, it is vital to address any potential bottlenecks. Scitara will offer an integration with Veeva Vault LIMS that will provide mutual customers with connected and compliant workflows that remove manual and paper-based processes, reduce the need for second-person review, and shrink the QC timeline to accelerate drug release.

“Life sciences companies are striving to take control of data, gain a greater degree of accountability to regulatory health authorities, and streamline working practices,” said Jason Boyd, senior director, Veeva Vault LIMS strategy. “Bringing benchtop data from instruments and applications securely into Veeva Vault LIMS in real-time will eliminate the need for point-to-point integrations or manual data entry. This is critical for enabling data-driven decisions to improve batch release times.”

Ajit Nagral, CEO and founder of Scitara, added: “The evolution of the lab depends on a single integrated ecosystem. The same fundamental principles apply, whether handling data from the lab or manufacturing processes. Scitara’s SIP provides a core infrastructure that establishes a dialogue across all controlling systems that guide the laboratory workflow: instruments, LIMS, e-notebooks, and manufacturing execution systems (MES), as well as supporting the way scientists and researchers exchange data too.”

To learn more about the partnership, visit https://scitara.com
phone +1 774-847-5034
email info@scitara.com
web https://scitara.com/
email 11 Apex Drive, Suite 300A, Marlborough, MA 01752
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI®▼ (teclistamab) in Combination with DARZALEX® (daratumumab) Subcutaneous (SC) Formulation and Lenalidomide in Relapsed or Refractory Multiple Myeloma

BEERSE, Belgium, 10 December 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI®▼ (teclistamab), the first European Commission approved BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX® (daratumumab) subcutaneous (SC) formulation and lenalidomide.1,2,3 According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed.1 A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy, including a proteasome inhibitor and immunomodulatory drug, with responses deepening over time.1 These data were presented during the 2022 American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, U.S. (Abstract #160).1
More info >>


White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement